National Institute for Health and Care Excellence (NICE) have been unable to recommend trastuzumab deruxtecan (Enhertu) as a cost-effective treatment for patients with advanced HER2-low breast cancer being treated by NHS England, according to final published guidance released on July 29, 2024.
[News] Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
LATEST
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy